Research & Publications
Our latest paper has been accepted for publication!
The paper is titled “SNIPSNP: Precision design of CRISPR/Cas9 knock-in reagents for variant correction and disease modeling”.
April 21, 2026
About us
Our focus
Our group focuses on developing targeted therapies for rare immunological conditions, such as primary immunodeficiency diseases and immunological conditions of unknown origin.
Our aim
We aim to optimize the CRISPR-Cas gene editing technology as a gene therapy in these diseases, and stratify the existing therapies – such as biologic drugs and small molecule inhibitors – to better target the underlying molecular pathways that malfunction in individual patients.
Our methods
We utilise custom genomics and high-throughput screening to understand immune diseases and optimize CRISPR-Cas9 genome editing towards safe and efficient use in patients. We work with cell models and patient material.
Our team
Our international team is based at the Norwegian Centre for Molecular Biosciences and Medicine (NCMBM) in Oslo, Norway. We have diverse backgrounds and expertise in biosciences and clinical medicine.
Our research
Our main projects involve optimising genome editing, along with personalised use of targeted therapies in rare diseases. We’re interested in rare and undiagnosed immunological diseases.
Publications
See our latest studies and research highlights in genome editing and novel genetic etiologies of immunological diseases in chronological order.
Latest news
Lab & Team Updates
Henriette has defended her Master thesis
Henriette has successfully defended her Master thesis. Congratulations!
February 4, 2026
Lab & Team Updates
Pavel has defended his PhD!
Pavel has successfully defended his thesis. Well done and congratulations!
January 23, 2026
Who supports us?
NCMBM - Norwegian Centre for Molecular Biosciences and Medicine
Visit site
The Research Council of Norway
Visit site
Norwegian Cancer Society
Visit site
South-Eastern Norway Regional Health Authority
Visit site
Astri og Birger Torsteds legat foundation
Visit site
Oslo University Hospital
Visit site
The Swedish Childhood Cancer Fund
Visit site
Academy of Finland
Visit site
Instrumentarium Science Foundation
Visit site
KLINBEFORSK
Visit site
Novo Nordisk Foundation
Visit site
We are proud to be a part of the new Centre of Excellence: The Precision Immunotherapy Alliance (PRIMA).